The US Supreme Court has ruled that when licensees seek a declaratory judgement of non-infringement, the patentee bears the burden of proof to show infringement.
On January 17, Actavis confirmed that the US District Court for the District of New Jersey found its US patent 7,704,984, which covers Lo Loestrin Fe birth control pills, to be valid and infringed by Lupin and Amneal.
The US Court of Appeals for the Federal Circuit has upheld a ruling which found that the US Patent and Trademark Office had been incorrectly calculating Patent Term Adjustment lengths.
Aurobindo’s European subsidiary is set to acquire Actavis’s commercial generic operations in seven Western European markets in a deal worth about €30 million ($40 million).
South African drug companies have been accused by advocacy organisations of planning a "deceptive" campaign to delay new laws which could see the introduction of more generic medicines.
UK IP firm HGF Limited has appointed Stephanie Loeffler as a partner in its London office.
Edwards Lifesciences Corporation secured another victory against its transcatheter heart valve rival Medtronic, whose CoreValve product was found to wilfully infringe one of Edwards’ patents in a verdict handed down on January 15.
Mumbai-based pharmaceutical company RPG Life Sciences Ltd has been found guilty of reverse domain name hijacking in a dispute fought at the WIPO’s Arbitration and Mediation Center.
Drug company Sandoz, the generic arm of Novartis, may not market generic versions of Allergan’s eye drop solution Lumigan before the last patent covering it expires in 2027, a district court decided on January 14.
UK law firm Potter Clarkson LLP has made changes to its team with the appointment of two senior managers.